1234479-76-5 Usage
Uses
Used in Pharmaceutical Industry:
ERK5-IN-1 is used as a potent selective ERK5 inhibitor for the development of novel therapeutic agents targeting various diseases. Its ability to inhibit EGFR-induced ERK5 autophosphorylation and ERK5 enzymatic activity makes it a valuable tool in the research and treatment of conditions associated with the ERK5 signaling pathway.
Used in Research Applications:
ERK5-IN-1 is employed as a research tool to study the role of ERK5 in various cellular processes and disease mechanisms. Its potent and selective inhibition of ERK5 allows researchers to investigate the specific functions and effects of this kinase in different experimental settings.
Used in Drug Discovery and Development:
ERK5-IN-1 serves as a lead compound in the development of new drugs targeting the ERK5 pathway. Its oral bioavailability and inhibitory properties make it a promising starting point for the design and optimization of more effective and selective ERK5 inhibitors for therapeutic use.
Check Digit Verification of cas no
The CAS Registry Mumber 1234479-76-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,4,4,7 and 9 respectively; the second part has 2 digits, 7 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1234479-76:
(9*1)+(8*2)+(7*3)+(6*4)+(5*4)+(4*7)+(3*9)+(2*7)+(1*6)=165
165 % 10 = 5
So 1234479-76-5 is a valid CAS Registry Number.
1234479-76-5Relevant academic research and scientific papers
Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a potent and selective inhibitor of big MAP kinase 1
Deng, Xianming,Yang, Qingkai,Kwiatkowski, Nicholas,Sim, Taebo,McDermott, Ultan,Settleman, Jeffrey E.,Lee, Jiing-Dwan,Gray, Nathanael S.
, p. 195 - 200 (2011/05/03)
Kinome-wide selectivity profiling of a collection of 2-amino-pyrido[2,3-d] pyrimidines followed by cellular structure-activity relationship-guided optimization resulted in the identification of moderately potent and selective inhibitors of BMK1/ERK5 exemp
